Evidence map›Paper›PMID 42603165›Full record

ReviewThe Journal of investigative dermatology2026

Regulatory T cells: From Foxp3 to tolerance-inducing therapies.

Hisato Iriki, Miho Mukai, Hayato Takahashi, Masayuki Amagai

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Journal of investigative dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hisato IrikiDepartment of Dermatology, Keio University School of Medicine, Tokyo, Japan; Laboratory for Skin Homeostasis, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan.
Miho MukaiDepartment of Dermatology, Keio University School of Medicine, Tokyo, Japan.
Hayato TakahashiDepartment of Dermatology, Keio University School of Medicine, Tokyo, Japan.
Masayuki AmagaiDepartment of Dermatology, Keio University School of Medicine, Tokyo, Japan; Laboratory for Skin Homeostasis, RIKEN Center for Integrative Medical Sciences, Kanagawa, Japan. Electronic address: amagai@keio.jp.

Funding

Montagna Symposium on the Biology of SkinR13AR009431 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI SANCY ANN LEACHMAN · 1986 to 2026
$785k
NIAMS NIH HHS R13 AR009431
6 · The paper itself

Abstract

The immune system balances self-tolerance and threat defense; regulatory T cells (Tregs) enforce this equilibrium. This review follows their journey from the disputed suppressor T-cell era to the Foxp3-defined lineage and then integrates how Tregs recalibrate antigen-presenting cells and cytokine networks to sustain immune quiescence and restore homeostasis. These insights shape emerging therapies that expand endogenous Tregs in vivo with low-dose IL-2 or employ ex vivo-engineered cells to re-establish immune balance. We conclude by outlining key challenges-stability, tissue targeting, and scalability-for durable tolerance and therapeutic applications of recently clarified Treg-mediated tissue-specific homeostasis.

Indexed as

Forkhead Transcription FactorsImmune ToleranceT-Lymphocytes, RegulatoryAnimalsHomeostasisHumansInterleukin-2Forkhead Transcription FactorsFOXP3 protein, humanInterleukin-2Foxp3Immune toleranceImmunotherapyRegulatory T cellsRegulatory T-cell therapy

Identifiers

PMID42603165
PMCPMC13615556

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.